Bioalliance PharmaAct Nom. Cat-P Aktie [WKN: A0HMXA / ISIN: FR0010095596]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Bioalliance PharmaAct Nom. Cat-P

30.06.14		Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo (Businesswire)
25.06.14		BioAlliance Pharma : Execution of a License Agreement with EMS for Sitavig® in Brazil (Businesswire)
20.06.14		Merger Plan with Topotarget: BioAlliance Pharma Has Received Pre-Approval for the Secondary Listing of the Shares of the Merged Company on NASDAQ OMX Copenhagen (Businesswire)
10.06.14		BioAlliance Pharma Strengthens Livatag® pAtent Protection in Japan Until 2032 (Businesswire)
10.06.14		BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at May 31, 2014 (Businesswire)
21.05.14		Definitive Merger Plan between BioAlliance Pharma and Topotarget (Businesswire)
19.05.14		BioAlliance Pharma SA: Livatag® Receives Fast Track Designation From the FDA for the Treatment of Primary Liver Cancer (Businesswire)
12.05.14		BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2014 (Businesswire)
05.05.14		BioAlliance Pharma Announces Major Achievements on Validive® (Businesswire)
30.04.14		BioAlliance Pharma SA: Quarterly information as of March 31, 2014 (Businesswire)
29.04.14		BioAlliance Pharma Publishes Its First Shareholder Newsletter (Businesswire)
16.04.14		BioAlliance Pharma and Topotarget Enter into Merger Agreement to Create a Leading Orphan Oncology Company (Businesswire)
14.04.14		BioAlliance Pharma Announces a New Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
08.04.14		BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions (Businesswire)
08.04.14		BioAlliance Pharma SA : Publication of the 2013 Registration Document (Businesswire)
03.04.14		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2014 (Businesswire)
02.04.14		BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea (Businesswire)
01.04.14		BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig® (Businesswire)
31.03.14		BioAlliance Pharma Collaborates with Penn Pharma on the Industrial Development of Validive® (Businesswire)
28.03.14		BioAlliance Pharma announces participation in the Smallcap Event On April 7th and 8th 2014 in Paris (GlobeNewswire)
28.03.14		BioAlliance Pharma Announces Participation in the Smallcap Event on April 7th and 8th 2014 in Paris (Businesswire)
19.03.14		BioAlliance Pharma: Sitavig® Licensing Strategy (Businesswire)
27.02.14		BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results (Businesswire)
18.02.14		BioAlliance Pharma SA: Strengthening and extension of the industrial protection of Livatag® until 2031 (Businesswire)
05.02.14		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at January 31, 2014 (Businesswire)
04.02.14		BioAlliance Pharma’s Partner, Sosei, Announces a Partnership With FUJIFILM Pharma for Commercialization Rights for Loramyc® in Japan (Businesswire)
23.01.14		BioAlliance Pharma : FDA Grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments (Businesswire)
13.01.14		BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at December 31, 2013 (Businesswire)
04.12.13		BioAlliance Pharma: Approval to start ReLive (Livatag®) Phase III Clinical Trial in Primary Liver Cancer in the U.S. and Germany (Businesswire)
04.12.13		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2013 (Businesswire)
14.11.13		BioAlliance Pharma : Quarterly information as of September 30, 2013 (Businesswire)
14.11.13		BioAlliance Pharma Strengthens Sitavig Patent Protection with New U.S. and South Korean issued Patents (Businesswire)
06.11.13		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2013 (Businesswire)
22.10.13		BioAlliance Pharma Announces Third Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
22.10.13		BioAlliance Pharma launches its new website (Businesswire)
07.10.13		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at September 30, 2013 (Businesswire)
30.09.13		BioAlliance Pharma : First Meeting of the International Advisory Board on Oral Mucositis and Development of Validive® (Businesswire)
19.09.13		BioAlliance Pharma: Key milestones and consolidated accounts (Businesswire)
05.09.13		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2013 (Businesswire)
02.08.13		BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at July 31, 2013 (Businesswire)
10.07.13		BioAlliance Pharma Expands and Strengthens Its Industrial Property Assets with Two Patent Grants (Businesswire)
03.07.13		BioAlliance Pharma Receives €4.3 Million in Funding from bpifrance (ex OSEO) To Accelerate the Industrial Development of Livatag(R) (Businesswire)
09.01.13		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2012 (Businesswire)
07.01.13		BioAlliance Pharma Announces the Launch of Oravig® in the United States by Its New Partner, Vestiq Pharmaceuticals (Businesswire)
03.01.13		BioAlliance Pharma receives a guarantee from Coface to finance its export activities (Businesswire)
20.12.12		BioAlliance Pharma Announces the Registration of Sitavig® in European Countries (Businesswire)
19.12.12		BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation without Modification of the Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
06.12.12		BioAlliance Pharma: First meeting of the DSMB of the ReLive trial and continuation without modification of the Phase III clinical trial with Livatag® in primary liver cancer (Businesswire)
06.12.12		BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2012 (Businesswire)
14.11.12		BioAlliance Pharma SA: Quarterly information as of September 30, 2012 (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Krypto-Influencer prognostiziert für 2025 gewaltige Rally beim Dogecoin

Solana Kurs-Prognose: 300 US-Dollar noch im Januar?

Pierer Mobility-Aktie knickt ein: KTM wird Produktionsstopp womöglich verlängern

Zinspolitik 2025: EZB plant Senkungen - wie schnell kommen sie?

Tesla-Aktie sackt ab: Absatzzahlen bleiben hinter Erwartungen

Apple-Aktie unter Druck: Apple kämpf offenbar mit China-Konkurrenz

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.01.2025 10:04
Kaufwert:	EUR
	Hinzufügen Speichern